196 related articles for article (PubMed ID: 24609468)
1. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.
Joerger M; Schaer-Thuer C; Koeberle D; Matter-Walstra K; Gibbons-Marsico J; Diem S; Thuerlimann B; Cerny T
Eur J Clin Pharmacol; 2014 Jun; 70(6):719-25. PubMed ID: 24609468
[TBL] [Abstract][Full Text] [Related]
2. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
Schmitt AM; Walter M; Herbrand AK; Jörger M; Moffa G; Novak U; Hemkens L; Kasenda B
BMJ Open; 2022 May; 12(5):e060453. PubMed ID: 35613810
[TBL] [Abstract][Full Text] [Related]
4. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
Conti RM; Bernstein AC; Villaflor VM; Schilsky RL; Rosenthal MB; Bach PB
J Clin Oncol; 2013 Mar; 31(9):1134-9. PubMed ID: 23423747
[TBL] [Abstract][Full Text] [Related]
6. Off-label drug use in oncology: a systematic review of literature.
Saiyed MM; Ong PS; Chew L
J Clin Pharm Ther; 2017 Jun; 42(3):251-258. PubMed ID: 28164359
[TBL] [Abstract][Full Text] [Related]
7. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
8. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.
Kurzrock R; Gurski LA; Carlson RW; Ettinger DS; Horwitz SM; Kumar SK; Million L; von Mehren M; Benson AB
Ann Oncol; 2019 Oct; 30(10):1647-1652. PubMed ID: 31373348
[TBL] [Abstract][Full Text] [Related]
9. Off-label use of anti-cancer drugs in India: to be or not to be!
Gota V; Patial P
J Cancer Res Ther; 2011; 7(1):35-9. PubMed ID: 21546740
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: A comprehensive cancer institution experience.
Fontanals S; Esteve A; González A; Ibáñez C; Mesía R; Clopés A
Pharmacol Res Perspect; 2024 Feb; 12(1):e1167. PubMed ID: 38193611
[TBL] [Abstract][Full Text] [Related]
11. Extent and Risks of Antipsychotic Off-Label Use in Children and Adolescents in Germany Between 2004 and 2011.
Schröder C; Dörks M; Kollhorst B; Blenk T; Dittmann RW; Garbe E; Riedel O
J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):806-813. PubMed ID: 28618239
[TBL] [Abstract][Full Text] [Related]
12. Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey.
Palčevski G; Skočibušić N; Vlahović-Palčevski V
Eur J Clin Pharmacol; 2012 Jul; 68(7):1073-7. PubMed ID: 22307225
[TBL] [Abstract][Full Text] [Related]
13. [Off label drug use in adult patients treated by anticancer chemotherapy].
Levêque D; Michallat AC; Schaller C; Ranc M
Bull Cancer; 2005 May; 92(5):498-500. PubMed ID: 15932813
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of off-label use of oral oncolytics at a community cancer center.
Kalis JA; Pence SJ; Mancini RS; Zuckerman DS; Ineck JR
J Oncol Pract; 2015 Mar; 11(2):e139-43. PubMed ID: 25604593
[TBL] [Abstract][Full Text] [Related]
15. An institutional audit of the use of novel drugs in pediatric oncology.
Lee J; Gillam L; Kouw S; McCarthy MC; Hansford JR
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1404. PubMed ID: 33939320
[TBL] [Abstract][Full Text] [Related]
16. Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.
Berlanga P; Ndounga-Diakou LA; Aerts I; Corradini N; Ducassou S; Strullu M; de Carli E; André N; Entz-Werle N; Raimbault S; Roumy M; Renouard M; Gueguen G; Plantaz D; Reguerre Y; Cleirec M; Petit A; Puiseux C; Andry L; Klein S; Bodet D; Kanold J; Briandet C; Halfon-Domenech C; Nelken B; Piguet C; Saumet L; Chastagner P; Benadiba J; Millot F; Pluchart C; Schneider P; Thouvenin S; Gambart M; Serre J; Abbou S; Leruste A; Cayzac H; Gandemer V; Laghouati S; Vassal G
JAMA Netw Open; 2023 Jul; 6(7):e2321568. PubMed ID: 37399010
[TBL] [Abstract][Full Text] [Related]
17. Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey.
Roila F; Ballatori E; Labianca R; De Braud F; Borgonovo K; Martelli O; Gallo C; Tinazzi A; Perrone F;
Tumori; 2009; 95(6):647-51. PubMed ID: 20210223
[TBL] [Abstract][Full Text] [Related]
18. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.
Lerose R; Musto P; Aieta M; Papa C; Tartarone A
Eur J Clin Pharmacol; 2012 May; 68(5):505-12. PubMed ID: 22166932
[TBL] [Abstract][Full Text] [Related]
19. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience.
Marín-Pozo JF; Duarte-Pérez JM; Sánchez-Rovira P
Medicine (Baltimore); 2016 May; 95(19):e3623. PubMed ID: 27175672
[TBL] [Abstract][Full Text] [Related]
20. [Off-label use of oncology drugs: national survey results].
González-Haba Peña E; Agustín Ferrández MJ; Mangues Bafalluy I; Alfredo López N; Fraga Fuentes MD; Marín Gil R; Martínez Bautista MJ; Clopés Estela A
Farm Hosp; 2015 Sep; 39(5):275-87. PubMed ID: 26546940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
